| 000 | nab a22 7a 4500 | ||
|---|---|---|---|
| 999 |
_c17942 _d17942 |
||
| 003 | PC17942 | ||
| 005 | 20250408122854.0 | ||
| 008 | 250407b xxu||||| |||| 00| 0 eng d | ||
| 040 | _cH12O | ||
| 041 | _aeng | ||
| 100 |
_9539 _aRuilope Urioste, Luis Miguel _eNefrología |
||
| 245 | 0 | 0 |
_aInvestigational calcium channel blockers for the treatment of hypertension. _h[revisión] |
| 260 |
_bExpert opinion on investigational drugs, _c2016 |
||
| 300 | _a25(11):1295-1309. | ||
| 500 | _aFormato Vancouver: Tamargo J, Ruilope LM. Investigational calcium channel blockers for the treatment of hypertension. Expert Opin Investig Drugs. 2016 Nov;25(11):1295-1309. | ||
| 501 | _aPMID: 27696904 | ||
| 504 | _aContiene 176 referencias | ||
| 520 | _aVoltage-gated Ca2+ channels are the primary route of Ca2+ entry in vascular smooth muscle cells, playing a key role in the regulation of arterial tone and blood pressure. Since the 60´s, L-type Ca2+ channel blockers (CCBs) have been widely used for the treatment of hypertension. Areas covered: T-type Ca2+ channels regulate vascular tone in small-resistance vessels and aldosterone secretion, and N-type channels expressed in sympathetic nerve terminals regulate the release of neurotransmitters. We performed a literature search in MEDLINE, PubMed and ClinicalTrials.gov to identify eligible studies published between January 2001 and March 2016 and reviewed the antihypertensive and renoprotective effects of four CCBs with different pharmacological profiles: azelnidipine (L-type), cilnidipine (L-/N-type) and benidipine and efonidipine (L-/T-type CCBs). Despite similar blood pressure lowering effects, L/N- and L/T-type CCBs, compared with L-type CCBs, decreased intraglomerular pressure, improved renal hemodynamics and provided a greater decrease in proteinuria even in patients already treated with renin-angiotensin-aldosterone inhibitors. Expert opinion: Dual L/N- and L/T-type CCBs may exhibit therapeutic advantages over L-type blockers in hypertensive patients with chronic kidney disease. Because clinical trials supporting these advantages present important biases, further large-scale, long-term comparative trials are needed to confirm that these differences translate into improved clinical outcomes. | ||
| 710 |
_986 _aServicio de Nefrología |
||
| 856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17942.pdf _ySolicitar documento |
||
| 942 |
_2ddc _cREV _n0 |
||